Difference between revisions of "Lab f2f Paris May 2014 minutes"
Jump to navigation
Jump to search
(Created page with "{| class="prettytable" |- | Welcome (Carolyn Knapik- CAP) |- | Introductions (All) |- | IHE Lab Overview (Francois Macary) |- | Agenda Review''' ''' (Francois Macary''') '''[...") |
|||
Line 1: | Line 1: | ||
+ | Back to '''[[Laboratory | IHE Laboratory Domain]]''' | ||
+ | |||
+ | Back to '''[[Laboratory_Technical_Committee | IHE Laboratory Technical Committee Page]]''' | ||
+ | |||
+ | ==Day 1 Minutes- May 12, 2014== | ||
{| class="prettytable" | {| class="prettytable" | ||
|- | |- | ||
| | | | ||
Welcome (Carolyn Knapik- CAP) | Welcome (Carolyn Knapik- CAP) | ||
− | |||
|- | |- | ||
| | | | ||
Introductions (All) | Introductions (All) | ||
− | |||
|- | |- | ||
| | | | ||
IHE Lab Overview (Francois Macary) | IHE Lab Overview (Francois Macary) | ||
− | |||
|- | |- | ||
| | | | ||
Agenda Review''' ''' (Francois Macary''') '''[http://wiki.ihe.net/index.php?title=LAB_F2F_Paris_May2014 http://wiki.ihe.net/index.php?title=LAB_F2F_Paris_May2014 ] | Agenda Review''' ''' (Francois Macary''') '''[http://wiki.ihe.net/index.php?title=LAB_F2F_Paris_May2014 http://wiki.ihe.net/index.php?title=LAB_F2F_Paris_May2014 ] | ||
− | |||
− | |||
− | |||
|- | |- | ||
| | | | ||
LAW Discussion | LAW Discussion | ||
− | |||
− | |||
* Looking at Figure 3-1: Have not focused on the fact, if LAW is good at covering middleware to Lab Analyzer Manager or other middleware- to possibly LTW; | * Looking at Figure 3-1: Have not focused on the fact, if LAW is good at covering middleware to Lab Analyzer Manager or other middleware- to possibly LTW; | ||
Line 37: | Line 34: | ||
* MSH-20 allows to communicate an alternate character set; | * MSH-20 allows to communicate an alternate character set; | ||
* Looking at Ed’s slides to introduce LAW background and introduction to IICC. | * Looking at Ed’s slides to introduce LAW background and introduction to IICC. | ||
− | |||
− | |||
IICC Tech Status | IICC Tech Status | ||
Line 54: | Line 49: | ||
* IHE connectathon overview – will add 2013 EU connectahon and Japanese 2013 – 1 analyzer and 3 analyzer managers – will see in afternoon; | * IHE connectathon overview – will add 2013 EU connectahon and Japanese 2013 – 1 analyzer and 3 analyzer managers – will see in afternoon; | ||
* WHO is very interested in sending list of standards to recommend for implementation tight relationship with ISO – consider reaching out to WHO eHealth initiatives – timeline is 9 months to get this developed | * WHO is very interested in sending list of standards to recommend for implementation tight relationship with ISO – consider reaching out to WHO eHealth initiatives – timeline is 9 months to get this developed | ||
− | |||
− | |||
|- | |- | ||
| | | | ||
Coffee Break | Coffee Break | ||
− | |||
|- | |- | ||
| | | | ||
Line 73: | Line 65: | ||
* AOE – vs SCI – solicited answer vs unsolicited answer – may not be important for the analyzer to be differentiated; | * AOE – vs SCI – solicited answer vs unsolicited answer – may not be important for the analyzer to be differentiated; | ||
* Consider adding a paragraph about pre-adoption to LAW | * Consider adding a paragraph about pre-adoption to LAW | ||
− | |||
− | |||
|- | |- | ||
| | | | ||
Lunch | Lunch | ||
− | |||
|- | |- | ||
| | | | ||
IHE Lab Profile Deployment Reports | IHE Lab Profile Deployment Reports | ||
− | |||
− | |||
* '''Japan'''- see slides; | * '''Japan'''- see slides; | ||
Line 95: | Line 82: | ||
** Must have description for codes of local systems?; | ** Must have description for codes of local systems?; | ||
** How to report Isolation testing – for example beta-lactamase activity? | ** How to report Isolation testing – for example beta-lactamase activity? | ||
− | |||
− | |||
* '''IICC (Jim Harrison) ''' | * '''IICC (Jim Harrison) ''' | ||
Line 119: | Line 104: | ||
*** May need to adjust planning of LCC publication based on the feedback we get from HL7. | *** May need to adjust planning of LCC publication based on the feedback we get from HL7. | ||
*** How would this use case be handled in FHIR? Need to decide if this use case is ONLY in the 80 % rule if so, then could consider. | *** How would this use case be handled in FHIR? Need to decide if this use case is ONLY in the 80 % rule if so, then could consider. | ||
− | |||
− | |||
* '''Feedback from the French WG on microbio vocabularies (Xavier Gansel)''' | * '''Feedback from the French WG on microbio vocabularies (Xavier Gansel)''' | ||
Line 127: | Line 110: | ||
** Do we need to add information to the patient?; | ** Do we need to add information to the patient?; | ||
** In France they have a national health record that is accessible by patients – structured data to professionals only otherwise. Diagram is not representative of all flows. | ** In France they have a national health record that is accessible by patients – structured data to professionals only otherwise. Diagram is not representative of all flows. | ||
− | |||
− | |||
* '''Review of new supplement proposals, and selection (Riki)''' | * '''Review of new supplement proposals, and selection (Riki)''' | ||
Line 150: | Line 131: | ||
*** Also not necessarily the order filler as the only source for this – would use LTW for this to get information to the analyzer manager / automation managers | *** Also not necessarily the order filler as the only source for this – would use LTW for this to get information to the analyzer manager / automation managers | ||
*** LIS report status of the test order without results (LTW) – possibly use this for the status update messages in LAW | *** LIS report status of the test order without results (LTW) – possibly use this for the status update messages in LAW | ||
− | |||
− | |||
− | |||
|- | |- | ||
| | | | ||
Line 159: | Line 137: | ||
* Support for the project from Beckman Coulter (discussed at NA conntectathon) and here GLIMS, Roche, Biomerieux and Inpeco | * Support for the project from Beckman Coulter (discussed at NA conntectathon) and here GLIMS, Roche, Biomerieux and Inpeco | ||
* Trying to find out if Japan has interest in expanding LDA and possibly using other Chapter 13 messages. | * Trying to find out if Japan has interest in expanding LDA and possibly using other Chapter 13 messages. | ||
− | |||
− | |||
|} | |} | ||
Meeting adjourned 5:15 PM | Meeting adjourned 5:15 PM | ||
+ | |||
+ | ==Day 2- May 13, 2014== |
Revision as of 15:32, 12 May 2014
Back to IHE Laboratory Domain
Back to IHE Laboratory Technical Committee Page
Day 1 Minutes- May 12, 2014
Welcome (Carolyn Knapik- CAP) |
Introductions (All) |
IHE Lab Overview (Francois Macary) |
Agenda Review (Francois Macary) http://wiki.ihe.net/index.php?title=LAB_F2F_Paris_May2014 |
LAW Discussion
IICC Tech Status
|
Coffee Break |
Open Items from CP (additions to OBR segment)
|
Lunch |
IHE Lab Profile Deployment Reports
|
Open Discussion
|
Meeting adjourned 5:15 PM